Genenta Science is a Milan-based biotechnology company developing first-in-class cell and gene therapies for solid tumors, with its lead program Temferon targeting glioblastoma multiforme. The company is transitioning into a strategic industrial consolidator focused on acquiring privately held businesses in Italian national-security regulated sectors including biotechnology, defense, cybersecurity, and critical infrastructure. Genenta funds its operations through equity offerings and convertible debt, has not yet generated product revenue, and operates in the highly regulated biotech sector facing typical clinical-stage development risks including regulatory approval uncertainties, capital requirements, and competitive pressures from larger pharmaceutical firms.